Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actinium (225Ac) rhPSMA 10.1 in mCRPC
NCT07414940Phase 2Recruiting
- Sponsor
- University College London
- Start
- Apr 2026
- Primary completion
- Mar 2031
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of 225Ac-rhPSMA-10.1 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University College London. Started Apr 2026; status: recruiting.
02
Drugs
225Ac-rhPSMA-10.1
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07414940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414940.